This morning Goldman said the S&P 500 is now trading near fair value based on several methodologies.
The explosive biotech rally of the last 2 years will end with a sector rotation (which I dont pretend to know when), but one thing is for sure.- Sectors ,all sectors are ultimately affected by the S&P
Insmed will have no profits for years( 3 is BCS),also watch for the coming dilution.- it will happen unless they partner.
Say nothing of competing with pharma powerhouses Novartis and Gilead,Cannacord and Wedbush agree
on the orphan for CF- it will not surpass 100 Million. (Wedbush 65-75 M 2018)at full market penetration.
(btw- that is a strong 25-30 % of the total market.)
Ultimately the results may change things - to speculate above what is known is the height of folly in biotech.
Now I just put our resident clowns on ignore and I see $250 off label and I dont have to even guess which idiot it was...anyway
In the past decade of this guilty pleasure I have posted my chart read - last one ( on the money) March22,
but now with the most important trade in 4 years, I will not. The responses have already been seen.
the chart is shifting and the trade is obvious.
I m sure it's this
2003 was a multibagger ..thanks to Cathy,these # look close
2009 +330% (Mostly Long)
2010 - ? ( major dilution &RS of shares)
2011 + 150% + - (Mostly short)
2012 +59%(couple of trades)
2013 +22% ( 1 trade-investing elsewhere) May3 initiated position
Funny, just told my Insmed bud that you will post during the cc. We are both laughing. Cannot believe your craving for attention and validation. Sadly though you still do not get it: you influence nothing on this board and are simply a source of amusement like the court jestors of old.